YMAB

Y-mAbs Therapeutics Inc

Add to Watchlist

Advanced Chart

8.520

+0.01(0.118%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.530

Open

8.520

VWAP

8.52

Vol

244.76K

Mkt Cap

386.68M

Low

8.515

Amount

2.09M

EV/EBITDA(TTM)

Total Shares

43.88M

324.39M

EV/OCF(TTM)

P/S(TTM)

4.48

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

21.04M

+0.66%

-0.305

+154.17%

22.52M

-14.99%

-0.480

+220%

21.02M

+13.86%

-0.285

+78.12%

Estimates Revision

The market is revising Upward the revenue expectations for Y-mAbs Therapeutics, Inc. (YMAB) for FY2025, with the revenue forecasts being adjusted by 0.65% over the past three months. During the same period, the stock price has changed by 109.34%.

Revenue Estimates for FY2025

Revise Upward

+0.65%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+24.59%

In Past 3 Month

Stock Price

Go Up

+109.34%

In Past 3 Month

11 Analyst Rating

-6.34% Downside

Wall Street analysts forecast YMAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for YMAB is 7.98 USD with a low forecast of 3.00 USD and a high forecast of 8.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

10 Hold

1 Sell

Hold

-6.34% Downside

Current: 8.520

Low

3.00

Averages

7.98

High

8.60

-6.34% Downside

Current: 8.520

Low

3.00

Averages

7.98

High

8.60

H.C. Wainwright

Robert Burns

Buy -> Neutral

downgrade

$11

2025-08-06

New

Reason

H.C. Wainwright

Robert Burns

Price Target

$11

2025-08-06

New

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Robert Burns downgraded Y-mAbs Therapeutics to Neutral from Buy with a price target of $8.60, down from $11, after the company entered into a merger agreement under which Serb will acquire Y-mAbs for $8.60 per share. The firm does not expect rival bidders to emerge.

Wedbush

Outperform -> Neutral

downgrade

2025-08-05

Reason

Wedbush

Price Target

2025-08-05

downgrade

Outperform -> Neutral

Reason

Wedbush downgraded Y-mAbs Therapeutics to Neutral from Outperform with an $8.60 price target after SERB Pharmaceuticals agreed to acquire Y-mAbs for $8.60 per share in cash.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

$19

2025-08-05

Reason

Cantor Fitzgerald

Price Target

$19

2025-08-05

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded Y-mAbs Therapeutics to Neutral from Overweight with a price target of $8.60, down from $19, after SERB Pharmaceuticals agreed to acquire Y-mAbs for $8.60 per share in cash.

Clear Street

Buy

Hold

downgrade

$17

2025-08-05

Reason

Clear Street

Price Target

$17

2025-08-05

downgrade

Buy

Hold

Reason

Clear Street downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $17, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash. The firm expects the transaction to go through as announced and does not expect another bidder, the analyst tells investors.

Truist

Buy

Hold

downgrade

$14

2025-08-05

Reason

Truist

Price Target

$14

2025-08-05

downgrade

Buy

Hold

Reason

Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

Brookline

Kemp Dolliver

Buy

Hold

downgrade

$8.60

2025-08-05

Reason

Brookline

Kemp Dolliver

Price Target

$8.60

2025-08-05

downgrade

Buy

Hold

Reason

Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Y-mAbs Therapeutics Inc (YMAB.O) is -6.25, compared to its 5-year average forward P/E of -13.93. For a more detailed relative valuation and DCF analysis to assess Y-mAbs Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.93

Current PE

-6.25

Overvalued PE

-3.82

Undervalued PE

-24.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.42

Current EV/EBITDA

-6.72

Overvalued EV/EBITDA

-2.89

Undervalued EV/EBITDA

-17.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.94

Current PS

4.47

Overvalued PS

18.92

Undervalued PS

0.96